Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04449679 · ClinicalTrials.gov registry record · NA
Real-Time Monitoring of Chemotherapy Side-Effects in Patients With Gastrointestinal Cancers, RT-CAMSS Study
A NA study of Clinical Stage II Esophageal Adenocarcinoma AJCC v8 and Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8, sponsored by Thomas Jefferson University.
- Completed
- Registry status
- NA
- Development phase
- 34
- Enrollment target
- 1
- Study location
NCT04449679: Completed NA study of Clinical Stage II Esophageal Adenocarcinoma AJCC v8 and Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8, sponsored by Thomas Jefferson University.
NCT04449679 is a NA study of Clinical Stage II Esophageal Adenocarcinoma AJCC v8 and Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8 that has completed, run by Thomas Jefferson University. The registered enrollment target is 34 participants, below the 86-participant average among 10 other Clinical Stage II Esophageal Adenocarcinoma AJCC v8 trials with a reported enrollment target (60% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04449679, a NA study of Clinical Stage II Esophageal Adenocarcinoma AJCC v8 and Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8, has completed, sponsored by Thomas Jefferson University.
- COMPLETED
- Registry status
- NA
- Development phase
- 34 participants
- Enrollment target
- 1
- Study location
Study Summary
This trial tests new methods and materials for the real-time chemotherapy-associated side effects monitoring support system (RT-CAMSS) in patients with gastrointestinal cancers undergoing chemotherapy. RT-CAMSS is a monitoring support system that provides patients with evidence-based information and side-effect management and coping skills, emotional support and validation, and proactive care via text messages and questionnaires as they undergo chemotherapy.
Primary Outcome
Will be measured through study accrual, attrition, and system usage frequencies. We aim for accrual at a rate of 50% to match our prior study but a rate over 30% will be feasible. The intervention will be considered feasible if attrition does not exceed 30%. 90% of participants reporting their symptoms at least once will be considered adequate.
Conditions Studied
Interventions
- OTHER Questionnaire Administration
- OTHER Consultation
- OTHER Patient Monitoring System
Study Locations (1)
Pennsylvania
- Thomas Jefferson University Hospital - Philadelphia
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 34 participants |
| Start Date | 2020-04-15 |
| Est. Completion | 2022-02-24 |
| Phase | NA |
What the finished NCT04449679 record still lists
NCT04449679 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 86-participant average among 10 other Clinical Stage II Esophageal Adenocarcinoma AJCC v8 trials with a reported enrollment target (60% lower).
The record links to 10 conditions, with Clinical Stage II Esophageal Adenocarcinoma AJCC v8 appearing as the primary indexed condition, and to 3 interventions - of which Questionnaire Administration is the first listed.
NCT04449679 reports a single indexed study location in Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT04449679 about?
NCT04449679 is a clinical study titled "Real-Time Monitoring of Chemotherapy Side-Effects in Patients With Gastrointestinal Cancers, RT-CAMSS Study". This trial tests new methods and materials for the real-time chemotherapy-associated side effects monitoring support system (RT-CAMSS) in patients with gastrointestinal cancers undergoing chemotherapy. RT-CAMSS is a monitoring support system that provides patients with evidence-based information and...
What is the current status of trial NCT04449679?
This trial is currently completed. It is a NA study. The enrollment target is 34 participants. The study started on 2020-04-15. Estimated completion is 2022-02-24.
What conditions does trial NCT04449679 study?
This clinical trial studies the following conditions: Clinical Stage II Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Esophageal Squamous Cell Carcinoma AJCC v8, Clinical Stage IIA Esophageal Adenocarcinoma AJCC v8, Clinical Stage II Gastric Cancer AJCC v8, Clinical Stage I Gastric Cancer AJCC v8.
What interventions are being tested in trial NCT04449679?
The interventions under investigation include: Questionnaire Administration (OTHER), Consultation (OTHER), Patient Monitoring System (OTHER).
Who is sponsoring clinical trial NCT04449679?
This trial is sponsored by Thomas Jefferson University, which has 292 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04449679 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Clinical Stage II Esophageal Adenocarcinoma AJCC v8
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT04449679's enrollment target sits among peer trials
34 7th of 10 higher than 4 of 10 other Clinical Stage II Esophageal Adenocarcinoma AJCC v8 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Clinical Stage II Esophageal Adenocarcinoma AJCC v8 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Feasibility of Auricular Acupressure for Appetite and Weight in Patients With Stage II-IV Gastric, Esophageal, and Pancreatic Cancer
RECRUITING · NA
-
Propranolol in Combination With Pembrolizumab and Standard Chemotherapy for the Treatment of Unresectable Locally Advanced or Metastatic Esophageal or Gastroesophageal Junction Adenocarcinoma
RECRUITING · Phase 2
-
Preoperative Hypofractionated Radiotherapy With FOLFOX for Esophageal or Gastroesophageal Junction Adenocarcinoma
RECRUITING · Phase 2
-
Adding Nivolumab to Usual Treatment for People With Advanced Stomach or Esophageal Cancer, PARAMUNE Trial
RECRUITING · Phase 2
-
Comparing Proton Therapy to Photon Radiation Therapy for Esophageal Cancer
RECRUITING · Phase 3
-
NBTXR3, Chemotherapy, and Radiation Therapy for the Treatment of Esophageal Cancer
RECRUITING · Phase 1
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT02897063 · 34 participants · Phase 1
Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure
- NCT03906617 · 34 participants · Phase 4
Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine
- NCT03992378 · 34 participants · NA
Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis
- NCT04047849 · 34 participants · Phase 4
Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI